Introduction {#S1}
============

Deep brain stimulation (DBS) is a developing experimental therapy for treatment resistant depression (TRD), and a range of grey and white matter targets are being studied, including the subcallosal cingulate (SCC), the ventral capsule/ventral striatum (VC/VS), the nucleus accumbens, the lateral habenula, the inferior thalamic peduncle, and the medial forebrain bundle ([@R1]--[@R8]). The SCC white matter target has been investigated most extensively with published data now reported for 77 patients implanted at eight separate centers ([@R9]). The response rate at 6 months in these open-label reports range between 33 and 87.5%. Combined results of all open-label studies (n=77) demonstrate a response rate of 53% at 6 months and 47% at 12 months, while remission rates are 27% at 6 months and 30% at 12 months ([@R1], [@R2], [@R10]--[@R15]). While generally positive, the results from open-label DBS studies in depression have not been replicated in large scale randomized controlled studies. A double-blind, randomized clinical trial failed to show efficacy in the VC/VS target and a similar one in the SCC was halted ([@R16], [@R17]). While sources of trial failure are likely multifactorial, the precision of surgical targeting is a critical and modifiable variable. Target identification and contact selection are known contributors to variability in efficacy across different clinical indications of DBS surgery. For example, even after 25 years of clinical experience the optimal imaging method to localize the subthalamic DBS target to treat Parkinson's disease remains a focus of ongoing refinement ([@R18], [@R19]). In comparison, the nuances of surgical targeting for DBS to treat depression are only beginning to be addressed. The accuracy ensures as well that contact selection is limited within certain anatomical boundaries, therefore considerably limiting all the possible combination of contacts to be selected for stimulation, and making procedural steps simpler.

Targeting of the SCC for DBS in the initial proof of principle study was guided by identifying the anatomical location of metabolic changes seen on PET scans with successful antidepressant response to other treatments ([@R1]). As the intended goal of DBS at this site was to modulate this 'SCC hub' as well as remote cortical and subcortical areas connected to it, the surgical target included both grey and white matter ([@R1]). All subsequent published studies studies (as well as the industry-sponsored SCC DBS trial) have followed this basic anatomical approach. However, this is a region of high anatomical variability without clear anatomical landmarks identifiable with routine in vivo imaging. As such, attempts to better define the 'optimal' implant location using standard anatomical coordinates have not proven useful ([@R20], [@R21]). Further, methods to confirm optimized lead implantation using microelectrode recordings are not yet reliable in this target, most likely because subsequent analyses have determined that therapeutic stimulation is primarily delivered in white matter ([@R10]).

Antidepressant effects of chronic high-frequency DBS likely involve modulation of a distributed, multi-region network in addition to local changes in the SCC region ([@R22]). Our group described in a retrospective study that clinical response to SCC DBS is mediated by direct impact on a combination of fiber bundles passing through the SCC region. These fiber bundles included bilateral forceps minor of the anterior corpus callosum connecting the right and left medial frontal cortices, the bilateral cingulum bundles connecting ipsilateral subcallosal cingulate to rostral, dorsal anterior, and midcingulate cortices; and medial branch of the uncinate fasciculus bilaterally connecting subcallosal cingulate and medial frontal cortex rostrally and subcallosal cingulate to the nucleus accumbens, anterior thalamus, and other subcortical regions caudally. All responders to SCC DBS, regardless of the time point chosen (6 months or 2 years) shared this common map ([@R23]). With this in mind, DBS targeting might now be optimized using a formalized "connectomics" approach ([@R24], [@R25]).

This pilot study tests the potential utility of using an *individualized* tractography map that is based on a group "connectome blueprint" of past responders to prospectively identify the SCC DBS surgical target. The hypothesis is that this method can guide surgical implantation and contact selection for chronic stimulation, thus reducing one of the key degrees of freedom impacting variability in DBS for TRD.

Methods {#S2}
=======

Participants and clinical protocol {#S3}
----------------------------------

Eleven consecutive patients with severe, chronic TRD were enrolled in a research protocol at Emory University testing safety and efficacy of SCC DBS for TRD (clinicaltrials.gov NCT00367003). Participants provided written informed consent to participate. The protocol was approved by the Emory University Institutional Review Board and the US Food and Drug Administration under an Investigational Device Exemption (G060028 held by H.S.M.) and is monitored by the Emory University Department of Psychiatry and Behavioral Sciences Data and Safety Monitoring Board.

The inclusion and exclusion criteria were essentially identical to those previously published by Holtzheimer et al. describing the first seventeen subjects implanted at Emory University ([@R15]). Key inclusion criteria consisted of: 18 to 70 years-old with a diagnosis of major depressive disorder (confirmed with the Structured Clinical Interview for *DSM-IV* and by the study psychiatrists (PRP, SJG, PEH, ALC)); a current depressive episode of at least 12 months without significant response to at least 4 adequate antidepressant treatments (scoring 3 or higher on the Antidepressant Treatment History Form and verified through medical records); lifetime failure or intolerance of electroconvulsive therapy or inability to receive electroconvulsive therapy; average score ≥ 20 on the 17-item Hamilton Depression Rating Scale (HDRS-17) averaged over the four weeks prior to surgery; Global Assessment of Functioning (GAF) of 50 or less; capacity to provide informed consent; and being able to relocate to the Atlanta area for 7 months ([@R26]--[@R29]).

Key exclusion criteria were defined as: clinically significant medical or psychiatric comorbidity (including personality disorders as determined by a review of medical records, the Structured Clinical Interview-II, and clinical examination); active substance use disorder; active suicidal ideation with plan or intent, a suicide attempt within the past 6 months, or more than 2 suicide attempts within the past 2 years; pregnancy or planning to become pregnant during the study; or contraindication for DBS surgery or chronic stimulation.

The preoperative evaluation lasted a minimum of 4 weeks. Chronic stimulation was initiated 4 weeks following surgery. Outcome was assessed weekly for 24 weeks of active stimulation using the HDRS-17. Response to treatment was defined as at least a 50% decrease and remission as 7 points or less on the HDRS-17 at 24 weeks. For any missing timepoint the previous observation was carried forward to the next timepoint. Medication changes were not allowed during the preoperative evaluation phase or the initial 24 weeks of chronic DBS. All patients received cognitive behavioral therapy. Patients were aware that they were receiving active stimulation, but were not privy to the criteria for target identification, contact selection or dose increases. All procedures were carried out at Emory University.

Procedure for subcallosal cingulate cortex deep brain stimulation {#S4}
-----------------------------------------------------------------

[Figure 1](#F1){ref-type="fig"} illustrates the procedure for subcallosal cingulate deep brain stimulation including pre-surgical planning, surgical procedure, and post-surgical analysis.

### A. Pre-surgical planning {#S5}

#### Magnetic resonance image acquisition and pre-processing {#S6}

High resolution T1 and diffusion-weighted images were collected within a single session for each subject on a research-dedicated Siemens 3T Tim-Trio scanner (Siemens Medical Solution, Malvern, PA, USA). All image data were preprocessed using tools from FSL software (FMRIB software Library, <http://www.fmrib.ox.ac.uk/fsl>)([@R30], [@R31]). High-resolution T1 images underwent skull stripping ([@R32]), image registration and normalization to an MNI152 template (MNI152 standard-space T1-weighted average structural temple image, FSL, FMRIB), and image segmentation into into grey matter (GM)/white matter (WM)/cerebrospinal fluid (CSF)([@R30], [@R33]). DWI data underwent the simultaneous eddy current and distortion correction with rotation of b-vector, image registration to T1, and local tensor fitting ([@R34]). Detailed image acquisition parameters and pre-processing steps are described in [Supplement 1](#SD1){ref-type="supplementary-material"}.

#### Prospective patient-specific target selection {#S7}

Structural connectivity-based target selection was performed in each patient using deterministic tractography (TrackVis, [TrackVis.org](TrackVis.org)) in the week before surgery ([@R35]). The target was defined on each patient's own MRI-DTI scan to impact the predefined 4-bundle white matter blueprint: uncinate fasciculus, forceps minor, cingulum bundle, and fronto-striatal fibers ([Figure 2](#F2){ref-type="fig"} -- left panel). The 'blueprint' was used as a archetype or reference template to prospective identify the optimal 'target' on the actual deterministic tractography scan. A 3 mm radius spherical region of interest (e.g., 'seed') was placed in the SCC corresponding to the estimated volume of tissue activated by standard DBS parameters. Volumes were defined using the predictive algorithm described in Chaturvedi et al. ([@R36])(for details, see [supplement 1](#SD1){ref-type="supplementary-material"}). Tracks from the seed were generated in each hemisphere. A dynamic evaluation of small modifications in the seed was performed independently by three investigators (HSM, PRP, KSC) to define the target location that best visually matched the reference 'blueprint'. A consensus target and lead trajectory was finalized with the neurosurgeon (REG) in the operating room ([Figure 2](#F2){ref-type="fig"} -- right panel), who planned the insertion of the leads avoiding cerebral vasculature and choosing the point of entry. Once the target was determined, a verification with tractography was confirmed, so it did not deviate from the presurgically defined plan.

### B. Surgical procedure {#S8}

#### Implantation surgery {#S9}

The surgical procedure for DBS lead and pulse generator implantation followed published methods ([@R15]). The combined tractography and anatomical images guided standard localization of the DBS lead tip and trajectory using a surgical planning workstation (StealthStation S7, Medtronic Inc, Louisville, CO). Bilateral DBS leads (Libra system, St Jude Medical, Plano, TX), each with 4 contacts (1.5 mm inter-contact spacing) were inserted and secured and with the patient awake and alert for testing initiated thereafter. Placement of the implantable pulse generator (IPG) and extension cables was performed under general anesthesia following completion of intra-operative testing.

#### Intraoperative testing {#S10}

Individual contacts on both leads (4 per side) with 4 interspersed sham stimulation conditions were tested in random order, with the clinical rater and patient blinded to the conditions. Stimulation parameters were the same as used for initial chronic stimulation (6mA, 130 Hz, 90 μsec). Stimulation of contacts in the presurgically-defined optimal target areas elicited distinct intraoperative responses ([@R37]). Each stimulation condition lasted 3 minutes, during which the patient was asked to report any behavioral changes. Contacts that generated a salient response were noted. These behaviorally salient responses usually have a change in patient's relationship with the external world (i.e. desire to be with one's partner doing something enjoyable) as well as an interoceptive change (i.e. "feeling lighter" or "warmer", a release of the heaviness of depression).

### C. Post-surgical analysis {#S11}

#### Contact Selection for chronic stimulation {#S12}

Final location of the DBS leads and respective optimal contact in each hemisphere for each subject were identified in native space based on post-surgical high-resolution computerized tomography (CT) images acquired on a LightSpeed16 (GE Medical System; resolution 0.46×0.46×0.65 mm^3^) and then transferred to T1 MRI space by linear transformation (FLIRT toolbox, FSL). The CT scan was performed about three weeks after surgery to allow for resolution of brain edema or electrode shift post-implantation. The post-surgical CT, preoperative MRI and preoperative DWI were merged. This hybrid 3D image was used to generate probabilistic tractography maps for each of the eight contacts using Fdt toolkit in FSL. Details of this probabilistic tractography method is described in [supplement 1](#SD1){ref-type="supplementary-material"}.

#### Initiation of chronic stimulation {#S13}

Final selection of a single right and left contact for chronic stimulation in each subject was made by comparing the postoperative ***probabilistic*** tractography map to the presurgical ***deterministic*** tractography map and confirming a match in the intended inclusion of the 4-white matter bundles. Intraoperative responses from the blinded acute stimulation were used as a secondary verification of a match between the intended and final contact location. In cases when two contacts had similar tractography patterns on the post-op probabilistic maps, the selection of one contact over the other was determined by the presence and quality of evoked intraoperative behavior.

Stimulation was initiated in all patients four weeks after surgery and continued for the 24 weeks open-label phase using standard stimulation settings (monopolar stimulation, current = 6 mA, frequency = 130 Hz, pulse width = 91 microseconds). In this pilot study of a refined targeting method, contact changes prior to 6 months were not made unless the participant had a deterioration in mood. Parameters remained stable, and adjustments were only made in current (6 to 8 mA) if HDRS-17 scores plateaued or worsened over a four-week interval. No changes in pulse width or frequency were made.

#### Post-treatment/Post-surgical confirmation of structural connectivity pattern in responders {#S14}

A common probabilistic structural connectivity map was created for responders at 24 weeks using methods previously developed ([@R23]). Whole brain tractography was calculated using bilateral stimulation volumes as seeds with the results binarized with a threshold value of 0.1%. A common population map of voxels shared by all subjects was generated (e.g., all subjects have these tracts) (see [supplement 1](#SD1){ref-type="supplementary-material"} for detailed methods).

#### Stimulation contact refinements after 6 months in nonresponders {#S15}

As the purpose of this study was to evaluate the utility of tractography-based targeting, alternative contacts were considered in patients who did not meet response criteria after 6 months of chronic stimulation. At this point, an evaluation of the individual probabilistic tractography maps for the remaining 6 contacts was made in order to search of an option that had an equivalent or better pattern of connectivity with respect to the first contact selection. If no contact met these criteria, parameters were not changed regardless of non-response status. No other parameter changes, such as frequency or pulse width, were employed, and no patients received stimulation on more than 1 contact per hemisphere. The maximum current allowed was 8 mA.

Statistical analysis {#S16}
--------------------

Characteristics of the study sample were summarized using mean and standard deviation for continuous variables, and percentage for categorical variables. Clinical response rates were calculated using HDRS-17 scores at 24 weeks and one year relative to the preoperative baseline. Probabilistic group tract maps were compared to the previously published tractography 'blueprint' using qualitative assessments of 3D common maps for both groups.

Results {#S17}
=======

Clinical outcomes {#S18}
-----------------

All 11 patients completed the protocol. Eight of 11 patients (72.7%) were responders and 6 were in remission after the initial 24 weeks (six months) of stimulation ([Table 2](#T2){ref-type="table"}, [Figure 3](#F3){ref-type="fig"}). At one year, nine of 11 patients (81.8%) were responders and 6 were in remission. One participant did not have the 12-month evaluation but was considered a responder because the 9 and 18-month evaluations indicated a 50% or greater response in HDRS-17. One of the three six-month nonresponders became a responder at one year. Two of the 11 patients never met response criteria, one with minimal variation in the depression scores, the other having a 40% decline at 12 months (participants 5 and 6 in [Table 2](#T2){ref-type="table"}).

Impact of Tractography-guided Targeting on Contact and Parameter Selection {#S19}
--------------------------------------------------------------------------

All patients had bilateral contacts that matched the four-bundle blueprint. Of the 22 individual contacts (2/patient) used for chronic DBS, only two (one contact in two patients) were changed within the first year of stimulation. One contact was changed in the first week of active stimulation due to deterioration and an atypical transient response (dysphoria and emotional lability without mania during the first minute of stimulation). Symptoms resolved with this contact change, and response was achieved and maintained without further changes. Both contacts selected matched the four-bundle blueprint. Eight of the 11 subjects had an increase in current from 6 to 8 mA within the first six months. No changes were made in pulse width or frequency.

The tractography maps in the three six-month nonresponders were reevaluated and only one participant warranted a contact change based on the preestablished criteria. In this case the new contact *better* matched the blueprint with more symmetric involvement of tracts in the subcortical fibers ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). This patient improved clinically but did not yet meet response criteria at one year; but became a sustained responder at a later timepoint.

The two remaining six-month nonresponders did not have alternative contacts that yielded an improvement over the initial selection, thus neither was changed. One subject was nonetheless a responder at 1 year; the other remained a long-term nonresponder ([Supplementary figure 2](#SD2){ref-type="supplementary-material"}).

Reproducibility of the deterministic tractography method for targeting {#S20}
----------------------------------------------------------------------

The common probabilistic tract map generated for all subjects at six months (both responders and non responders) demonstrates inclusion of forceps minor, uncinate fasciculus, fronto-striatal fibers and cingulum bundle as intended. This common response map matches the connectome blueprint defined by the responders in the initial cohort ([Figure 4](#F4){ref-type="fig"}).

Discussion {#S21}
==========

This pilot study tested the implementation of a modified method for SCC DBS targeting using prospective tractography. The four-bundle white matter blueprint was reliably defined and precisely implanted in each of the 11 subjects. Stimulation maintained at these targets resulted in good clinical outcomes. These results support the utility of a ***group probabilistic*** tractography blueprint ([Figure 2A](#F2){ref-type="fig"}) for individualized, ***patient-specific, deterministic*** tractography targeting ([Figure 2B](#F2){ref-type="fig"}), confirming retrospective findings previously published ([@R23]).

While this open-label study was not designed or powered to directly compare the efficacy of DBS to our previous cohort ([@R15]) or any other SCC DBS targeting method or cohort ([@R2], [@R10]--[@R14]), the 73% response rates at 6 months and 82% at 1 year are notable, with stable and even increasing response rates up to the 1 year endpoint. For practical consideration in the planning and implementing any future SCC DBS study, reliance on the tractography-defined optimal location resulted in few contact changes and current adjustments within and across subjects over the duration of the protocol.

We can conclude that based on the analysis of this cohort, deterministic tractography can be reliably performed in an individual subject to choose the implantation target in the SCC, augmenting the standard approach that relies solely on anatomical landmarks or stereotactic coordinates ([@R21]).

One of the most important benefits of our tractography-guided methodology was the simplified programming in the active stimulation phase during the clinical study. Establishing that stimulation through the appropriately selected contact in the patient matched the predefined tractography blueprint gave reassurance to the team that the response is not likely to depend on further interrogation of the parameter space. Instead, a focus on other contributors to nonresponse - unrelated to stimulation - could be pursued, as is true for pharmacological antidepressant interventions. Such factors include more systematic attention to variability in clinical or demographic characteristics of TRD subjects who meet the already restricted inclusion/exclusion criteria as well as examination of potential imaging, genetic or other biomarkers that might further define this SCC-responsive TRD subtype ([@R38]). Given the few number of non-responders in this small cohort, these types of analyses will require larger samples.

An unresolved issue is which combination of the 4 bundles within our tractography blueprint is sufficient to achieve antidepressant response to SCC DBS. The independent contribution of individual bundles or the relative importance of left versus right sided stimulation is currently unknown. Post-hoc analysis of the relative contribution of the right sided contacts to left sided contacts demonstrates symmetric contribution to the forceps minor from each hemisphere in all subjects (data not shown). However, limitations of this generation of deterministic and probabilistic tractography methods are that they cannot disambiguate direct connections between the SCC and the frontal cortex from fibers of passage in and around the stimulated zone. Similarly, the lack of precise resolution within the stimulated zone cannot separate forceps minor from uncinate fasciculus. Next generation scanners and diffusion sequences do have potential to allow more detailed studies of the critical pathways mediating the SCC DBS antidepressant effects ([@R39]--[@R41]). Concurrent physiological recordings and/or functional imaging will also be required to further address mechanisms mediating DBS antidepressant effects facilitated by targeting these pathways ([@R42]).

While our results cannot explain the reasons for failed randomized controlled trials of this or other DBS targets for neuropsychiatric disorders, these findings do support the use of tractography-based surgical targeting to reduce variability in the direct effects of stimulation on the patient-specific brain circuitry. In turn, we propose that our new methodology enables more consistent and precise modulation of a predefined collection of axonal pathways in all study subjects. This strategy enables a more controlled analysis of the population and streamlines the stimulation programming. Standardization of targeting and programming algorithms informed by these results may help to refine study design and interpretation of outcomes of future studies.
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###### 

Patient Characteristics

  Characteristics                           Mean (SD) or Count
  ----------------------------------------- ----------------------
  Age at Surgery (years)                    48.73 (10.10)
  Sex                                       Female (9), Male (2)
  Employed at Time of Surgery               2 of 11
  Baseline HDRS-17                          23.09 (2.55)
  Duration of Current Episode (months)      36.36 (21.11)
  Medications in Current Episode            7.18 (1.83)
  Age at First Depressive Episode (Years)   20.45 (11.32)
  Number of Depressive Episodes             3.82 (1.47)

###### 

(HDRS-17 monthly)

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Patient     Baseline   Stim On   1 Month   2 Months   3 Months   4 Months   5 Months   6 Months   9 Months   12 Months
  ----------- ---------- --------- --------- ---------- ---------- ---------- ---------- ---------- ---------- ------------------------------------
  1           24.25      27        21        22         15         21         17         13         11         9

  2           27.5       12        14        9          17         7          9          6          12         10

  3           23.75      21        19        19         25         15         11         9          10         5

  4           22         15        16        13         13         16         10         6          10         9

  5           22.75      22        19        18         19         16         17         16         23         19

  6           20.25      21        19        19         16         16         18         17         11         12

  7           26.25      20        18        19         26         17         11         12         8          6

  8           19.5       7         10        12         5          3          2          7          4          1

  9           25.25      18        8         6          6          6          7          6          10         10[\*](#TFN1){ref-type="table-fn"}

  10          21         17        6         5          4          9          3          6          1          2

  11          21.5       15        9         8          15         10         9          6          8          5

  Mean\       23.09\     17.73\    14.45\    13.64\     14.64\     12.36\     10.36\     9.45\      9.82\      8\
  (Std Dev)   (2.55)     (5.42)    (5.32)    (6.04)     (7.39)     (5.63)     (5.35)     (4.3)      (5.47)     (5.04)
  -------------------------------------------------------------------------------------------------------------------------------------------------

Patient missed 1 year appointment (returned for 18 month appointment). This is the 9 month score
